CCR RNAi initiative overview

CCR RNAi 计划概述

• 批准号: 7292883
• 负责人: natasha caplen
• 金额: --
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7292883
• 关键词: CCR; RNAi; initiative; overview

The Gene Silencing Section (GSS) aims to be a center of excellence and expertise within CCR for the study and application of RNAi in mammalian cells. The scientific and clinical developments in the field of RNAi are rapidly impacting our understanding of the role of RNA silencing mechanisms on the control of normal and disease related gene expression, including cancer. Further, technological developments utilizing RNAi analysis to study gene function, the development of new model systems, improved understanding of drug: target interactions and target identification through large scale-screening, including whole genome, RNAi approaches (siRNA and shRNA) are now highly realistic. The GSS continues to contribute the CCR RNAi initiative in a number of ways including: (A) Out reach and assistance: We have delivered a number of lectures to interested CCR laboratories, Branches and CCR Faculty/Working Group/Program based groups with the aim of educating individuals as to the current status of the RNAi field and the role of GSS specifically. Time has been spent advising to various degrees investigators from many CCR laboratories and Branches including, CTB, CCBB, EIB, GB, HAMB, NOB, POB, UOB, LBC, LCP, LCB, LCRC, LCMB, LCCTP, LCO, LEC, LEI, LG, LHC, LICB, LM, LMB, LMI, LTIB, LMP, LP, LPG, SBL. (B) Information technology: Critical to the dissemination of RNAi technology will be computer-based access to RNAi-related information. We our now posting regular updates to the GSS website within the OSTP, OD, CCR web-site reporting siRNA characterization data that is available to CCR investigators and we envisage shortly introducing pages describing access to shRNA resources and standardized protocols. In addition, Dr. Caplen has had input into the development of a centralized RNAi database at NCBI which should become fully operational in Fall 2005. (C) Initial Gene Targets and expansion to whole genome analysis: During Fall 2003 and early 2004 an extensive out-reach program was conducted to identify key gene targets where RNAi analysis would improve our understanding of the role of a gene/protein in the cancer process and or as an anti-cancer target. As will be described below and within other projects GSS has now established RNAi resources, appropriate assays and down-stream functional analysis for a significant proportion of these targets. Success with this initial analysis has now given us sufficient confidence to begin the process of expanding our remit to consider whole genome RNAi approaches. (D) RNAi resources: Synthetic siRNAs to approximately 400 cancer-associated genes are now available to GSS and we have completed characterization of the RNAi mediated by the siRNAs corresponding to 85 of these genes. CCR investigators can access this characterization data using an intramural MTA mechanism. During FY05 we supplemented our synthetic siRNA resources with 300 shRNA clones purchased to support a specific collaborative project. Recent advancements in shRNA resources developed by the extramural community and available through purchase have given us sufficient confidence to invest in a whole genome human shRNA library. Work on the establishment of this library as a working entity will begin in Fall 2005. (E) Relationship to other CCR initiatives: We continue to also interact with other CCR initiatives, programs, faculties and groups including MTDP/MTP, DTP, RTP, MWG, ABCC and the AMI.

基因沉默科 (GSS) 旨在成为 CCR 内研究和应用哺乳动物细胞 RNAi 的卓越中心和专业知识。 RNAi 领域的科学和临床发展正在迅速影响我们对 RNA 沉默机制在控制正常和疾病相关基因表达（包括癌症）中的作用的理解。此外，利用 RNAi 分析来研究基因功能的技术发展、新模型系统的开发、对药物的理解的提高：通过大规模筛选（包括全基因组、RNAi 方法（siRNA 和 shRNA））实现靶标相互作用和靶标识别，现在已变得非常现实。 GSS 继续以多种方式为 CCR RNAi 倡议做出贡献，包括： (A) 外展和援助：我们已向感兴趣的 CCR 实验室、分支机构和基于 CCR 教员/工作组/项目的团体举办了许多讲座，目的是教育个人了解 RNAi 领域的现状以及 GSS 的具体作用。我们花费时间为许多 CCR 实验室和分支机构的不同程度的研究人员提供建议，包括 CTB、CCBB、EIB、GB、HAM​​B、NOB、POB、UOB、LBC、LCP、LCB、LCRC、LCMB、LCCTP、LCO、LEC、LEI、LG、LHC、LICB、LM、LMB、LMI、LTIB、LMP、LP、 液化石油气、SBL。 (B) 信息技术：RNAi 技术传播的关键是通过计算机获取 RNAi 相关信息。我们现在在 OSTP、OD、CCR 网站内的 GSS 网站上定期发布更新，报告可供 CCR 研究人员使用的 siRNA 表征数据，并且我们预计很快会引入描述 shRNA 资源和标准化协议的访问的页面。此外，Caplen 博士还参与了 NCBI 集中 RNAi 数据库的开发，该数据库应于 2005 年秋季全面投入使用。 (C) 初始基因靶标和扩展到全基因组分析：2003 年秋季和 2004 年初，进行了一项广泛的外展计划，以确定关键基因靶标，其中 RNAi 分析将提高我们对基因/蛋白质在癌症过程中和/或作为抗癌靶标的作用的理解。如下文和其他项目中所述，GSS 现已针对这些靶标中的很大一部分建立了 RNAi 资源、适当的检测方法和下游功能分析。初步分析的成功让我们有足够的信心开始扩大我们的职权范围，考虑全基因组 RNAi 方法。 (D) RNAi 资源：GSS 现已提供大约 400 个癌症相关基因的合成 siRNA，并且我们已经完成了与其中 85 个基因相对应的 siRNA 介导的 RNAi 的表征。 CCR 调查人员可以使用壁内 MTA 机制访问此特征数据。 2005 财年期间，我们购买了 300 个 shRNA 克隆来补充我们的合成 siRNA 资源，以支持特定的合作项目。校外社区开发并可通过购买获得的 shRNA 资源的最新进展使我们有足够的信心投资全基因组人类 shRNA 文库。该图书馆作为工作实体的建立工作将于 2005 年秋季开始。 (E) 与其他 CCR 倡议的关系：我们还继续与其他 CCR 倡议、计划、院系和团体进行互动，包括 MTDP/MTP、DTP、RTP、MWG、ABCC 和 AMI。